Academic Appointments

Contact

  • Academic
    abbas67@stanford.edu
    University - Other Teaching/Research Department: Adult Neurology Position: Instructor

Additional Info

  • Mail Code: 5151

All Publications

  • Monitoring of cancer ferroptosis with [18F]hGTS13, a system xc- specific radiotracer. Theranostics Moses, A., Malek, R., Kendirli, M. T., Cheung, P., Landry, M., Herrera-Barrera, M., Khojasteh, A., Granucci, M., Bukhari, S. A., Hooper, J. E., Hayden-Gephart, M., Dixon, S. J., Recht, L. D., Beinat, C. 2025; 15 (3): 836-849

    Abstract

    Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, characterized by resistance to conventional therapies and poor survival. Ferroptosis, a form of regulated cell death driven by lipid peroxidation, has recently emerged as a promising therapeutic target for GBM treatment. However, there are currently no non-invasive imaging techniques to monitor the engagement of pro-ferroptotic compounds with their respective targets, or to monitor the efficacy of ferroptosis-based therapies. System xc-, an important player in cellular redox homeostasis, plays a critical role in ferroptosis by mediating the exchange of cystine for glutamate, thus regulating the availability of cysteine, a crucial precursor for glutathione synthesis, and influencing the cellular antioxidant defense system. We have recently reported the development and validation of [18F]hGTS13, a radiopharmaceutical specific for system xc-. Methods: In the current work, we characterized the sensitivity of various cell lines to pro-ferroptotic compounds and evaluated the ability of [18F]hGTS13 to distinguish between sensitive and resistant cell lines and monitor changes in response to ferroptosis-inducing investigational compounds. We then associated changes in [18F]hGTS13 uptake with cellular glutathione content. Furthermore, we evaluated [18F]hGTS13 uptake in a rat model of glioma, both before and after treatment with imidazole ketone erastin (IKE), a pro-ferroptotic inhibitor of system xc- activity. Results: Treatment with erastin2, a system xc- inhibitor, significantly decreased [18F]hGTS13 uptake and cellular glutathione content in vitro. Dynamic PET/CT imaging of C6 glioma-bearing rats with [18F]hGTS13 revealed high and sustained uptake within the intracranial glioma and this uptake was decreased upon pre-treatment with IKE. Conclusion: In summary, [18F]hGTS13 represents a promising tool to distinguish cell types that demonstrate sensitivity or resistance to ferroptosis-inducing therapies that target system xc-, and monitor the engagement of these drugs.

    View details for DOI 10.7150/thno.101882

    View details for PubMedID 39776801

    View details for PubMedCentralID PMC11700874

  • OPTIMIZING BRAIN CANCER THERAPY: BALANCING TUMOR ERADICATION AND NORMAL TISSUE PRESERVATION WITH BPM31510 Khojasteh, A., Kendirli, M., Narain, N., Nagpal, S., Nastke, M., Gesta, S., Recht, L. OXFORD UNIV PRESS INC. 2024

    View details for DOI 10.1093/neuonc/noae165.0498

    View details for Web of Science ID 001362575700015

  • IMPROVED ANTI-GLIOBLASTOMA EFFICACY BY BRG399, A NOVEL ORAL MICROTUBULE BINDING AGENT Kendirli, M., Nastke, M., Aristizabal-Henao, J., Khojasteh, A., Kiebish, M., Chimmanamada, D., Vishnudas, V., Recht, L., Gesta, S. OXFORD UNIV PRESS INC. 2024

    View details for DOI 10.1093/neuonc/noae165.0499

    View details for Web of Science ID 001362575500007